Celularity Inc. (CELU) director awarded 28,847 RSUs that vest immediately

Rhea-AI Filing Summary

Celularity Inc. director Vincent LeVien reported receiving 28,847 restricted stock units (RSUs) of Class A common stock under the company’s 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the filing states that these RSUs vest immediately upon grant as of 01/12/2026. After this equity award, LeVien beneficially owns 153,847 shares of Celularity Class A common stock in total, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeVien Vincent

(Last) (First) (Middle)

C/O CELULARITY INC.

170 PARK AVENUE

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Celularity Inc [ CELU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/12/2026		A		28,847(1)	A	$0.00	153,847(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.

2. Includes 28,847 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.

	/s/ Vincent LeVien	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Celularity Inc. (CELU) disclose in this Form 4/A?

The filing discloses that director Vincent LeVien received an equity award of 28,847 restricted stock units (RSUs) of Celularity Inc. Class A common stock on 01/12/2026.

How many Celularity (CELU) RSUs were granted to director Vincent LeVien?

Director Vincent LeVien was granted 28,847 RSUs, with each RSU representing the right to receive one share of Celularity Inc. Class A common stock.

When do the newly granted Celularity (CELU) RSUs to Vincent LeVien vest?

The filing states that the 28,847 RSUs granted to Vincent LeVien vest immediately upon grant as of 01/12/2026.

What is Vincent LeVien’s total beneficial ownership in Celularity (CELU) after this RSU grant?

Following the reported transaction, Vincent LeVien beneficially owns 153,847 shares of Celularity Inc. Class A common stock, held directly.

What equity plan was used for the RSU grant to the Celularity (CELU) director?

The 28,847 RSUs granted to director Vincent LeVien were issued under the Celularity Inc. 2021 Equity Incentive Plan, according to the filing.

Was there a cash price paid for the Celularity (CELU) RSUs reported in this Form 4/A?

The transaction table lists the price for the 28,847 Class A common stock underlying the RSUs as $0.00, indicating no cash purchase price for this grant.